Ascendis Pharma to Announce Second Quarter 2024 Financial Results
Ascendis Pharma A/S (NASDAQ: ASND) has revealed its plans to announce the financial results for the second quarter of 2024. This report will be made available after the U.S. financial markets close on a specified date, in line with the company's commitment to keeping its investors and stakeholders informed about significant developments.
Details of the Announcement
On the same day as the report, the company will host a conference call accompanied by a live webcast to discuss the financial outcomes and provide a thorough business update. This event is scheduled for 4:30 p.m. Eastern Time, offering an opportunity for interested parties to participate in the conversation about the company’s performance and future prospects.
How to Join the Conference Call
If you’re interested in learning more about Ascendis Pharma's quarterly performance, we highly recommend joining the live webcast. Participants can access the conference call through the specific links provided by the company. Additionally, a replay of the webcast will be available for 30 days after the event, allowing stakeholders to review the discussion at their convenience.
About Ascendis Pharma A/S
Ascendis Pharma is committed to developing innovative therapeutic solutions using its proprietary TransCon technology platform. The company strives to position itself as a leading integrated biopharmaceutical entity, focusing on improving the health and wellbeing of patients globally. By leveraging cutting-edge science, Ascendis Pharma aims to create new therapies that can significantly enhance patient outcomes.
Core Philosophy and Values
At the core of Ascendis Pharma's mission are the fundamental values that steer its operations: Patients, Science, and Passion. These principles reflect the company's commitment to delivering high-quality medical advancements while prioritizing patient needs and maintaining scientific integrity. With its headquarters in Copenhagen, Denmark, and additional facilities in Europe and the United States, Ascendis Pharma supports a wide range of research and development initiatives.
Contact Information
For any inquiries related to investor relations or media questions, Ascendis Pharma has designated personnel available:
Investor Contacts:
Tim Lee
Ascendis Pharma
Phone: +1 (650) 374-6343
Email: tle@ascendispharma.com
Email: ir@ascendispharma.com
Media Contact:
Melinda Baker
Ascendis Pharma
Phone: +1 (650) 709-8875
Investor Relations:
Patti Bank
ICR Westwicke
Phone: +1 (415) 513-1284
Email: patti.bank@westwicke.com
Frequently Asked Questions
When will Ascendis Pharma report its Q2 2024 results?
Ascendis Pharma is set to report its second quarter 2024 financial results on September 3, 2024, after the markets close.
How can I participate in the conference call?
The conference call can be accessed through specific links provided by the company, allowing participants to engage in discussions about the financial results.
What technology does Ascendis Pharma use?
The company utilizes its innovative TransCon technology platform to develop advanced therapies aimed at improving patient outcomes.
Who should I contact regarding investor relations?
For investor relations inquiries, you can reach Tim Lee at +1 (650) 374-6343 or via email at tle@ascendispharma.com.
What are the core values of Ascendis Pharma?
The core values of Ascendis Pharma are Patients, Science, and Passion, which emphasize their commitment to patient-focused research and innovation.
